Yes, Humacyte has achieved a major regulatory milestone with its flagship acellular tissue engineered vessel (ATEV), securing formal approval from the U.S. Food and Drug Administration (FDA) for urgent arterial repair following extremity vascular trauma. Additionally, the company has advanced subsequent clinical pipelines—such as applications for kidney dialysis access and coronary bypass grafting—through ongoing regulatory reviews and investigational new drug applications.